EFFECTS OF TANSHINONE IIA COMBINED WITH MONTELUKAST ON COAGULATION, INFLAMMATION AND TH17/TREG CELL IMMUNITY IN CHILDREN WITH HENOCH-SCHONLEIN PURPURA

Ting Guo¹, Jizu Ling¹, Xu Fu², Zhongbin Tao¹, Yuning Li^{1, *} 

¹Department of Pediatrics, The First Hospital of Lanzhou University, Lanzhou, PR China - ²Lanzhou First People's Hospital, Lanzhou, PR China

Objective: To investigate the effect of tanshinone IIA combined with montelukast on coagulation, inflammatory response and Th17/Treg cell immunity in children with Henoch-Schonlein purpura. 

Methods: From January 2014 to January 2017, 84 children with anaphylactoid purpura were divided into an observation group (n = 42) and a control group (n = 42). The control group received routine treatment, while the observation group was treated with tanshinone IIA combined with montelukast based on routine treatment. Coagulation function, inflammatory reaction and Th17/Treg cell immune level were compared between the two groups. 

Results: After treatment, the total effective rate was 95.23% in the observation group in comparison to 80.95% in the control group, a statistically significant difference (P<0.05). After treatment, the APTT level in both groups was significantly higher than that before treatment, while the FIB level in the observation group was significantly lower than that before treatment, also a statistically significant difference (P<0.05). After treatment, the level of IL-12 in both groups was significantly higher than that before treatment. Meanwhile, the level of IL-17 in the observation group was significantly lower than that in the control group (P<0.05), and the difference was statistically significant (P<0.05). Before treatment, no statistical difference was seen in Th17/Treg cell immunity (P>0.05). After treatment, the level of Th17 and Th17/Treg cells in both groups was significantly higher than that before treatment; moreover, the Treg cell level in the observation group was significantly higher than that in the control group (P<0.05), and the difference was statistically significant (P<0.05). After treatment, the CD₁₉⁺ level of the two groups was significantly lower than that before treatment, and the difference was statistically significant (P<0.05). Meanwhile, the level of CD₃⁺CD₄⁺/CD₈⁺ in the observation group was significantly higher than that in the control group (P<0.05). 

Conclusion: Tanshinone IIA combined with montelukast can improve coagulation function as well as reduce the inflammatory response and Th17/Treg cell immunity in children with purpura.